Comparison of Ketamine and Morphine in Pain Relief

Comparison of Intravenous and Intranasal Ketamine and Intravenous Morphine in Pain Relief of Bone Fractures

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140524017812N4

Enrollment

153

Registered

2023-10-12

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: bone fracture pain. Condition 2: bone fracture pain. Condition 3: BONE FRACTURE PAIN. Condition 4: bone fracture pain. Fracture of shoulder and upper arm Fracture of lumbar spine and pelvis Fracture of lower leg, including ankle Fracture of femur

Interventions

Intervention 1: Intervention group: intranasal ketamine. in this group, they will receive 1mg/kg nasal ketamine along with 1 cc of normal saline intravenously. Ketamine is manufactured by PANPHARMA, G

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: all patients with bone fracture who refer the emergency ward.

Exclusion criteria

Exclusion criteria: previous use of analgesic head trauma or loss of consciousness counterindication to ketamine such as heart disease, ICP rise, hepatic failure, psychosis, pregnancy allergy to ketamine counterindication to morphine such as (respiratory depression, asthma, use of monoamine oxidase inhibitors, opioid abuse, gastrointestinal obstruction) allergy to morphine Lack of consent to participate in the study Hepatic failure pregnancy

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0-15-30-60 minute. Method of measurement: 0-10 pain scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Faridaalaee

Tabriz University of Medical Sciences

grf.aalae@yahoo.com+98 41 3382 9540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026